MedTrace Logo

Gamma Entrainment Stimulation for Cognitive Dysfunction After aSAH

NCT06346015 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-04-03

No results posted yet for this study

Summary

The goal of this clinical trial is to Explore and verify whether 40Hz audio and binaural beat 40Hz audio can improve the postoperative cognitive dysfunction seen in patients with aneurysmal subarachnoid hemorrhage. This study is a single-center, prospective, randomized, controlled clinical trial. Patients with aneurysmal subarachnoid hemorrhage were selected and randomized into intervention group (audio adjuvant group) and control group (conventional treatment group). Patients in the intervention group will receive audio therapy after surgery, and patients in the control group will receive usual care. EEG, fMRI and mRS scores were evaluated after 3 months of follow-up.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal
  • Cognitive Dysfunction

Interventions

PROCEDURE

Gamma Entrainment Stimulation

Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months. (Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）

Sponsors & Collaborators

  • Shanghai Joyingmed Sensory Stimulation Lab

    collaborator UNKNOWN

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Guangzhi Shi, MD · Beijing Tiantan Hospital

  • Jun Yang, MD · Beijing Tiantan Hospital

  • Yu Chen, MD · Beijing Tiantan Hospital

  • Ke Wang, MD · Beijing Tiantan Hospital

  • Cunyang Li, MD · Beijing Tiantan Hospital

  • Junwei Lv, MD · Shanghai Joyingmed Sensory Stimulation Lab

  • Nianze Chen, MD · Shanghai Joyingmed Sensory Stimulation Lab

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2025-03-31
Completion
2025-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06346015 on ClinicalTrials.gov